Kyverna Therapeutics, Inc..
KYTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. Their primary focus is on engineering and developing therapies that target and modulate the immune system to treat conditions such as multiple sclerosis, myasthenia ...Show More
Better Health for All
40
Kyverna Therapeutics is focused on developing cell therapies for autoimmune diseases, which aligns with the goal of better health for all. KYV-101, their lead product, is in Phase 2 trials for stiff person syndrome, myasthenia gravis, and lupus nephritis
1
. Clinical data shows sustained efficacy and tolerability in lupus nephritis patients, with no high-grade CRS or ICANS observed
2
,
3
,
4
,
5
. The company is investing significantly in R&D, with $37.4 million spent in Q1 2025
6
,
7
, a substantial increase from $22.5 million in Q1 2024
8
,
9
. They have aligned with the FDA on registrational pathways for SPS and MG
10
,
11
. Kyverna also obtained exclusive licenses from the NIH for their CAR T-cell therapies
12
,
13
,
14
. However, a workforce reduction of 16% was implemented in Q1 2025
15
,
16
, which could potentially impact the pace of development. The price accessibility of their therapies is currently unknown.
Fair Money & Economic Opportunity
0
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies, not a financial institution.
1
The company does not offer lending, deposit services, or other financial products to consumers.
2
Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its core business operations.
Fair Pay & Worker Respect
0
No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While articles mention benefits such as company-subsidized medical, dental, and vision, a 401(k) retirement plan with a company match, unlimited flexible PTO, and competitive salaries for various roles,
1
they do not provide the necessary percentages, ratios, or incident rates to score against the rubric's quantitative thresholds. Specifically, there is no data for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or the percentage of the workforce covered by health insurance.
2
Fair Trade & Ethical Sourcing
0
No evidence available to assess Kyverna Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No relevant data was found in the provided articles to assess Kyverna Therapeutics, Inc. against the 'Honest & Fair Business' ethical value.
1
The single article indicated that data retrieval was throttled, resulting in no available information for any of the KPIs.
2
Kind to Animals
0
No evidence available to assess Kyverna Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Kyverna Therapeutics, Inc. against any of the 'No War, No Weapons' KPIs. The articles either contained no relevant quantitative data
1
or were inaccessible.
2
Planet-Friendly Business
0
No evidence available to assess Kyverna Therapeutics, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No evidence was found in the provided articles regarding Kyverna Therapeutics, Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities.
1
The articles primarily focus on financial results, clinical trial updates, corporate strategy, and regulatory actions concerning T-cell malignancy risks.
2
There is no information on community engagement, cultural impact assessments, local employment, grievance mechanisms, partnerships, or any other metrics relevant to this ethical value.
3
Safe & Smart Tech
10
Kyverna Therapeutics states compliance with EU GDPR and the UK Data Protection Act 2018, including specific mentions of Article 9(1) and Article 89(1) GDPR for processing special categories of data for scientific research.
1
The company commits to using the minimum personally identifiable information possible in clinical studies and retains personal data only as long as necessary, with anonymized data potentially used indefinitely for research or statistical purposes.
2
EEA residents are granted comprehensive rights to access, correct, erase, object to processing, restrict processing, transfer data, and withdraw consent.
3
Users also have choices to opt-out of marketing communications, control cookies, and opt-out of targeted online advertising.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Kyverna Therapeutics, Inc. on Zero Waste & Sustainable Products.